Table 2.
Change in severity scores of liver disease and plasma biomarkers during follow-up in HIV-infected patients with advanced HCV-related cirrhosis.
| Δx (95%CI) | p | q | |
|---|---|---|---|
| Liver disease | |||
| LSM (kPa) | −9.1 (−12.4; −5.8) | <0.001 | <0.001 |
| HVPG (mmHg) | −2.6 (−4.4; −0.8) | 0.005 | 0.011 |
| CTP score | −0.2 (−0.3; 0) | 0.024 | 0.045 |
| Bacterial translocation | |||
| LPS (EU/ml) | 0.1 (−0.2; 0.4) | 0.372 | 0.431 |
| LBP (μg/ml) | −0.6 (−0.8; −0.4) | <0.001 | <0.001 |
| sCD14 (μg/ml) | 0.1 (−0.3; 0.5) | 0.589 | 0.643 |
| FABP-2 (ng/ml) | 0.1 (−0.1; 0.3) | 0.291 | 0.388 |
| Inflammatory response | |||
| IP-10 (a.u.) | −699.5 (−994.7; −404.3) | <0.001 | <0.001 |
| MCP-1 (a.u.) | −47.3 (−152.4; 57.7) | 0.377 | 0.431 |
| IL-8 (a.u.) | −55.9 (−80.9; −31) | <0.001 | <0.001 |
| IL-1β (a.u.) | −2.4 (−5.4; 0.6) | 0.116 | 0.186 |
| IL-18 (a.u.) | −901.2 (−1,300; −488.7) | <0.001 | <0.001 |
| IL-6 (a.u.) | −12.5 (−35.2; 10.2) | 0.280 | 0.388 |
| TNF-α (a.u.) | −1 (−2.6; 0.6) | 0.228 | 0.341 |
| IL-1RA (a.u.) | −11.9 (−20.4; −3.3) | 0.006 | 0.013 |
| sRANKL (a.u.) | −0.6 (−4.3; 3.1) | 0.746 | 0.779 |
| OPG (a.u.) | −82.7 (−116.1; −49.2) | <0.001 | <0.001 |
| Endothelial dysfunction | |||
| sVCAM-1 (a.u.) | −1,400 (−2,100; −786.4) | <0.001 | <0.001 |
| sICAM-1 (a.u.) | −74.3 (−95.5; −53.1) | <0.001 | <0.001 |
| TNFR-I (a.u.) | −9 (−17.8; −0.2) | 0.044 | 0.076 |
| Coagulopathy | |||
| PAI-1 (a.u.) | −468 (−733; −203) | 0.001 | 0.001 |
| D-dimer (a.u.) | 547.4 (−511.3; 1,606.1) | 0.311 | 0.393 |
| Angiogenesis | |||
| VEGF-A (a.u.) | −18.2 (−30; −6.4) | 0.003 | 0.006 |
| VEGF-R1 (a.u.) | 0 (−6.9; 6.9) | 0.999 | 0.999 |
Statistics: Values are expressed as the estimated average of the increase (Δx = x2-x1) and 95% of confidence interval (95%CI). p-Values were calculated by GLM mixed models. p-Values, raw p-values; q-values, p-values corrected for multiple testing using the false discovery rate (FDR) with Benjamini and Hochberg procedure. The statistically significant differences are shown in bold.
HCV, hepatitis C virus; HIV, human immunodeficiency virus; LSM, liver stiffness measurement; CTP, Child-Pugh-Turcotte; HVPG, hepatic venous pressure gradient; mmHG, millimeter of mercury; kPa, kilopascals; a.u., arbitrary units of fluorescence; sCD14, soluble CD14; LPS, lipopolysaccharide; FABP2, fatty acid-binding protein 2; LBP, lipopolysaccharide binding protein; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; TNF-α, tumor necrosis factor alpha; IP-10, IFN-γ-inducible protein 10; MCP1, monocyte chemoattractant protein-1; OPG, osteoprotegerin; sRANKL, soluble receptor activator of nuclear factor- kappaB ligand; sVCAM-1, soluble vascular cell adhesion molecule 1; sICAM-1, soluble intercellular cell adhesion molecule 1; sTNFR-1, soluble tumor necrosis factor receptor 1; PAI-1, plasminogen activator inhibitor-1; VEGF-A; vascular endothelial growth factor A; sVEGF-R1, soluble receptors for vascular endothelial growth factor.